No time for for­mal­i­ties, Acor­da scraps FDA meet­ing in scram­ble to re-file CVT-301

With the clock tick­ing down to a fi­nal de­ci­sion on key patents, one of its big in­vestors ag­i­tat­ing for change and fac­ing a se­ri­ous de­lay on its late-stage res­cue plan, Acor­da’s ex­ec­u­tive team isn’t wast­ing any time on un­nec­es­sary meet­ings.

The biotech filed a no­tice with the SEC to­day say­ing that based on its dis­cus­sions with reg­u­la­tors, they can skip a Type A meet­ing and move to re-file their ap­pli­ca­tion for CVT-301 with­out tak­ing time for any such for­mal­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER